GET DAILY SIGNALSImmuCell (ICCC) Shares Advance +5.4% on Solid Q3 Sales Momentum
Key Takeaways
- ICCC shares have gained roughly 5.4% over the past 30 days, moving from about $9.88 to near $10.42 and trading toward the upper end of a recent range.
- The advance followed preliminary third-quarter 2026 results showing total sales up 46% year over year, which triggered a sharp, higher-volume rally in mid-October.
- First Defense, led by the flagship Tri-Shield product, continues to capture share in the U.S. calf-scours biologics market.
- A two-phase manufacturing expansion aims to more than triple First Defense capacity by the end of 2027, supporting longer-term supply and cost goals.
- Gross margin has been volatile as former Re-Tain-related costs shift into cost of goods sold and quarterly manufacturing output fluctuates.
- For additional detail, investors can review ImmuCell's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are approaching tickers like ICCC.
Current Market Snapshot
ImmuCell Corporation (ICCC) trades as a small-cap animal-health name that has generally moved within a modest band in recent weeks. After holding around $9.88 in late September and dipping to roughly $9.60 in early October, the stock jumped sharply in mid-October and has since consolidated near $10.42. The move keeps the shares close to the upper portion of their recent trading range, reflecting generally constructive investor sentiment following the company's preliminary third-quarter sales update.
The stock's trading is relatively thin, which can make day-to-day price swings more pronounced than they might be for larger issuers. Even so, the underlying trend has been supported by consistent execution in the company's core calf-health franchise rather than by any single speculative catalyst. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ImmuCell Corporation (ICCC) Business Overview and Competitive Position
ImmuCell Corporation, headquartered in Portland, Maine, is an animal-health biologics company focused on improving calf health and productivity. Its core franchise, First Defense, provides immediate immunity to newborn calves through colostrum-derived, orally delivered antibodies that target the principal viral and bacterial causes of scours, a potentially deadly form of neonatal calf diarrhea. Key products in the line include Tri-Shield, the premium flagship offering, as well as Dual-Force and a recently launched functional feed format.
ImmuCell competes in a specialized niche within the broader dairy and beef cattle market. Management has emphasized that First Defense commands premium pricing because it delivers differentiated, immediate protection. The company has steadily increased its share of U.S. category spending and the number of animals treated, a sign that its product differentiation is translating into commercial traction against larger animal-health peers. Investors follow the stock closely because supply and manufacturing execution, rather than demand alone, have historically been the key constraints on growth.
Recent Developments Driving ICCC
The most significant recent development was ImmuCell's preliminary, unaudited third-quarter 2026 sales announcement. Total sales reached $8.0 million, up 46.0% from the year-ago quarter, with domestic sales up 29.2% to $6.9 million. Management attributed the growth in part to a depressed prior-year comparison, but also pointed to expanded sales coverage and improved manufacturing reliability. Tri-Shield grew 51%, Dual-Force grew 36%, and the functional feed line grew 37% from the third quarter of 2025.
That announcement coincided with a notable single-session rally and a jump in trading volume. For the first nine months of 2026, total sales reached $25.6 million, a 27.8% increase from the prior year. Separately, the company has been executing a two-phase capacity expansion announced earlier in 2026. The program leverages equipment and facilities originally built for the now-paused Re-Tain mastitis program, with a roughly $3.5 million freeze-drying phase and a roughly $4.5 million liquids-processing phase expected to more than triple current capacity.
Earnings results have been mixed on margins. First-quarter 2026 gross margin improved to 45.0%, while second-quarter gross margin declined to 33.9% as Re-Tain-related costs moved into cost of goods sold and output dipped. Second-quarter net income of $1.8 million, or $0.20 per share, also benefited from a $2 million legal settlement with the former Re-Tain contract manufacturer.
2026 Outlook and What Investors Should Watch
Several factors are likely to shape ImmuCell's trajectory through the remainder of 2026 and into 2027. The company has said it will report full third-quarter financial results and host a conference call in mid-November 2026, which should clarify gross-margin trends and the sustainability of recent sales growth. Investors will also be watching whether the company can maintain its market-share gains and whether rising output improves product availability without compressing margins.
The manufacturing expansion remains a central theme. If the freeze-drying and liquids-processing phases proceed on schedule, capacity is expected to more than triple by the end of 2027, which could ease a long-running supply constraint and support further revenue growth. At the same time, the business is tied to seasonal demand patterns in the cow-calf market and to factors such as calf values and farm economics, which can shift from quarter to quarter. Competitive pressure from larger animal-health companies and the timing of capital spending are additional variables that could influence results. From what I see, the capacity build-out stands out as a key long-term driver worth monitoring closely.
Using AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Trading Bots can help investors explore systematic approaches to names such as ICCC without replacing their own fundamental work. I find it useful to review how different strategies have performed across similar small-cap healthcare stocks when evaluating entry points or risk levels. This keeps the research process grounded while adding a layer of data-driven perspective.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ICCC in upward trend: 10-day moving average crossed above 50-day moving average on October 16, 2026
The 10-day moving average for ICCC crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
ICCC moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 105 of 140 cases where ICCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for ICCC moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICCC as a result. In 97 of 123 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for ICCC turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
ICCC broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.970) is normal, around the industry mean (2.974). ICCC's P/E Ratio (128.250) is considerably higher than the industry average of (-0.899). Projected Growth (PEG Ratio) (8.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (2.847) is also within normal values, averaging (439.237).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of products for cattle health
Industry Biotechnology
Advertisement